The glucose monitoring device market in the Asia Pacific is expected to reach USD 0.54 billion by 2026 from USD 0.38 billion in 2021, at a CAGR of 7.42% from 2021 to 2026. The Asia Pacific market is more attention-grabbing as it is at a growing stage and is estimated to lead the market in the future due to the large patient pool in this region.
Glucose monitoring devices are used to detect the sugar level in our blood and are of several kinds, including a glucose meter, testing strips, and lancets. The usage of these devices consumes less time than glucose testing by customary methods in laboratories. These devices can be controlled easily as they are portable so convenient to carry. They offer the facility of monitoring glucose levels in our blood as it tests quantitatively. The glucose monitoring strip devices lead the market with maximum share and also has the highest growth rate.
The increasing prevalence of diabetes cases is due to an unhealthy lifestyle, low diet, excess alcohol consumption, and lack of physical activity. The growing baby boomer population, increasing incidence of an unhealthy lifestyle, and food habits are resulting in considerable differences in health are expected to expand the market growth during the forecast period.
However, this market faces inevitable loss due to some manufacturing defect or error in results. Besides, the accessibility of Continuous Glucose Monitors (CGM) also hinders the growth of the market.
This research report on the Asia Pacific Glucose Monitoring Device Market has been segmented and sub-segmented into the following categories:
Regionally, the Asia Pacific market is the quickest growing region in the global market due to the existence of briskly enhancing healthcare technology, enormous patient pool, and increasing healthcare expenditure. China and India are the major contributing countries towards the market over the forecast period.
China is dominating the APAC region during the analysis period because of its well-progressed technology, an increasing number of diabetes patients, a considerable amount spent on healthcare, and mounting support from the government towards the R&D. Around 1.2 million people with type-1 diabetes and 0.1 billion people are diagnosed with type-2 diabetes in China.
The Indian market is the second-largest leading market in the APAC. Growing necessity for blood glucose monitoring devices, funds, and investments for research, early identification of diabetes propels the market growth.
A list of key companies profiled in this APAC Monitoring Device Market profiled in this report are Roche Diagnostics, LifeScan, Bayer Health care, Abbott Diabetes care Inc., AgaMatrix Inc., Arkray Inc., Medtronic, DexCom Inc., Nova Biomedical Corporation, and Terumo Europe NV.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Device Type
5.1.1 Continuous Wearable Devices
5.1.1.1 Sensors
5.1.1.2 Transmitters and Activators
5.1.2 Self-Monitoring Devices
5.1.2.1 Blood Glucose Meters
5.1.2.2 Blood Glucose Strips
5.1.2.3 Lancets
5.1.2.4 Haemoglobin A1C testing Kits
5.2 By Application
5.2.1 Hospitals
5.2.2 Clinics and Diagnostic Centers
5.2.3 Home Setting
5.2.4 Ambulatory Settings
6. Geographical Analysis
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Roche Diagnostics
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 LifeScan
8.3 Bayer Health care
8.4 Abbott Diabetes care Inc
8.5 AgaMatrix Inc
8.6 Arkray Inc
8.7 Medtronic
8.8 DexCom Inc
8.9 Nova Biomedical Corporation
8.10 Teruma Europe NV
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
